ID: ALA363682

Max Phase: Preclinical

Molecular Formula: C18H15BrO2

Molecular Weight: 343.22

Molecule Type: Small molecule

Representations

Synonyms (1): 2-Bromo-Benzylidene Tetralone
Synonyms from Alternative Forms(1):

Canonical SMILES:  COc1ccc2c(c1)CC/C(=C\c1ccccc1Br)C2=O

Standard InChI:  InChI=1S/C18H15BrO2/c1-21-15-8-9-16-12(11-15)6-7-14(18(16)20)10-13-4-2-3-5-17(13)19/h2-5,8-11H,6-7H2,1H3/b14-10+

Standard InChI Key:  ZHOQTMYSBFYMPC-GXDHUFHOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 343.22

Molecular Weight (Monoisotopic): 342.0255

AlogP: 4.67

#Rotatable Bonds: 2

Polar Surface Area: 26.30

Molecular Species: NEUTRAL

HBA: 2

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 2

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa:

CX LogP: 4.95

CX LogD: 4.95

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.74

Np Likeness Score: -0.42

References

1. Yee SW, Simons C..  (2004)  Synthesis and CYP24 inhibitory activity of 2-substituted-3,4-dihydro-2H-naphthalen-1-one (tetralone) derivatives.,  14  (22): [PMID:15482941] [10.1016/j.bmcl.2004.08.040]

2. Yee SW, Jarno L, Gomaa MS, Elford C, Ooi LL, Coogan MP, McClelland R, Nicholson RI, Evans BA, Brancale A, Simons C..  (2005)  Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays.,  48  (23): [PMID:16279770] [10.1021/jm0501681]

3. Aboraia AS, Makowski B, Bahja A, Prosser D, Brancale A, Jones G, Simons C..  (2010)  Synthesis and CYP24A1 inhibitory activity of (E)-2-(2-substituted benzylidene)- and 2-(2-substituted benzyl)-6-methoxy-tetralones.,  45  (10): [PMID:20655626] [10.1016/j.ejmech.2010.07.001]

Source

Source(1):

• Scientific Literature